valproic acid has been researched along with Movement Disorders in 34 studies
Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.
valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.
Movement Disorders: Syndromes which feature DYSKINESIAS as a cardinal manifestation of the disease process. Included in this category are degenerative, hereditary, post-infectious, medication-induced, post-inflammatory, and post-traumatic conditions.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Alphaxalone (up to 5 mg/kg) did not exert a significant action against amygdala-kindled seizures in rats, or against pentetrazole- or aminophylline-induced convulsions in mice." | 7.71 | Interaction of the neurosteroid alphaxalone with conventional antiepileptic drugs in different types of experimental seizures. ( Borowicz, KK; Czuczwar, SJ; Kleinrok, Z; Kowalska, A; Swiader, M; Zadrozniak, M, 2002) |
| "Here, we aimed at determining whether a well-acknowledged animal model of autism spectrum disorders, the valproic acid model, displays motor impairments and whether they may correlate with social deficits and neuronal loss within motor brain areas." | 3.88 | Motor Impairments Correlate with Social Deficits and Restricted Neuronal Loss in an Environmental Model of Autism. ( Al Sagheer, T; Balbous, A; Fernagut, PO; Francheteau, M; Haida, O; Jaber, M; Matas, E, 2018) |
| " Alphaxalone (up to 5 mg/kg) did not exert a significant action against amygdala-kindled seizures in rats, or against pentetrazole- or aminophylline-induced convulsions in mice." | 3.71 | Interaction of the neurosteroid alphaxalone with conventional antiepileptic drugs in different types of experimental seizures. ( Borowicz, KK; Czuczwar, SJ; Kleinrok, Z; Kowalska, A; Swiader, M; Zadrozniak, M, 2002) |
| "New-onset movement disorders have been frequently reported in association with the use of antiseizure medications (ASMs)." | 2.82 | Movement disorders associated with antiseizure medications: A systematic review. ( Pavuluri, S; Schmidt, CM; Situ-Kcomt, M; Snehal, I; Taraschenko, O; Zhou, DJ, 2022) |
| "Among psychiatric disorders the acute symptoms of schizophrenia are exacerbated by enhanced GABA-ergic function." | 2.36 | Pharmacology of GABA. ( Meldrum, B, 1982) |
| "Benign myoclonic epilepsy in infancy (BMEI) is a well-defined electro-clinical syndrome, classically associated with a good prognosis." | 1.40 | [Benign myoclonic epilepsy in infancy: natural history and behavioral and cognitive outcome]. ( Carreras-Sáez, I; Domínguez-Carral, J; Fournier-Del Castillo, MC; García-Peñas, JJ; Jiménez-Echevarría, S; Pérez-Jiménez, MÁ, 2014) |
| "Individuals treated with combined valproate-lamotrigine rarely present late adverse effects (unrelated to introduction and titration)." | 1.38 | Late adverse effects of the coadministration of valproate and lamotrigine. ( Moreira, B; Thome-Souza, S; Valente, KD, 2012) |
| "A large cohort of 1528 patients with parkinsonism was analyzed, gathering data on demography, motor and non-motor characteristics, as well as the final etiologic diagnoses based on established criteria." | 1.36 | The differential diagnoses of parkinsonism: findings from a cohort of 1528 patients and a 10 years comparison in tertiary movement disorders clinics. ( Munhoz, RP; Teive, HA; Werneck, LC, 2010) |
| "To quantify changes in ictal seizure semiology during rapid withdrawal of carbamazepine (CBZ) and valproate (VPA) from a monoregimen in presurgical evaluation." | 1.31 | Influence on ictal seizure semiology of rapid withdrawal of carbamazepine and valproate in monotherapy. ( Hopp, P; Kerling, F; Kirchner, A; Pauli, E; Stefan, H; Wang, Y; Zhou, D, 2002) |
| " for 6 weeks, and anticonvulsant and adverse effects during this period were studied." | 1.28 | Valproic acid in amygdala-kindled rats: alterations in anticonvulsant efficacy, adverse effects and drug and metabolite levels in various brain regions during chronic treatment. ( Fisher, JE; Hönack, D; Löscher, W; Nau, H, 1989) |
| " Accordingly, camptocormia is a dose-dependent side effect of valproate." | 1.27 | Camptocormia, a new side effect of sodium valproate. ( Iivanainen, M; Kiuru, S, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 14 (41.18) | 18.7374 |
| 1990's | 2 (5.88) | 18.2507 |
| 2000's | 5 (14.71) | 29.6817 |
| 2010's | 11 (32.35) | 24.3611 |
| 2020's | 2 (5.88) | 2.80 |
| Authors | Studies |
|---|---|
| Rissardo, JP | 1 |
| Caprara, ALF | 1 |
| Durante, Í | 1 |
| Zhou, DJ | 1 |
| Pavuluri, S | 1 |
| Snehal, I | 1 |
| Schmidt, CM | 1 |
| Situ-Kcomt, M | 1 |
| Taraschenko, O | 1 |
| Al Sagheer, T | 1 |
| Haida, O | 1 |
| Balbous, A | 1 |
| Francheteau, M | 1 |
| Matas, E | 1 |
| Fernagut, PO | 1 |
| Jaber, M | 1 |
| Yu, F | 1 |
| Wang, Z | 2 |
| Tanaka, M | 1 |
| Chiu, CT | 1 |
| Leeds, P | 1 |
| Zhang, Y | 2 |
| Chuang, DM | 1 |
| Domínguez-Carral, J | 1 |
| García-Peñas, JJ | 1 |
| Pérez-Jiménez, MÁ | 1 |
| Fournier-Del Castillo, MC | 1 |
| Carreras-Sáez, I | 1 |
| Jiménez-Echevarría, S | 1 |
| Yang, C | 1 |
| Yuan, G | 1 |
| Cui, W | 1 |
| Li, R | 1 |
| Bamford, A | 1 |
| Crowe, BH | 1 |
| Hacohen, Y | 1 |
| Lin, JP | 1 |
| Clarke, A | 1 |
| Tudor-Williams, G | 1 |
| Sancho-Shimizu, V | 1 |
| Vincent, A | 1 |
| Lim, M | 1 |
| Pullaperuma, SP | 1 |
| Johannsen, J | 1 |
| Nickel, M | 1 |
| Schulz, A | 1 |
| Denecke, J | 1 |
| Moyal, D | 1 |
| Sanyal, S | 1 |
| Khanna, A | 1 |
| Munhoz, RP | 1 |
| Werneck, LC | 1 |
| Teive, HA | 1 |
| Rana, AQ | 1 |
| Ali, A | 1 |
| Böke, BN | 1 |
| García-Ramos, R | 1 |
| Moreno Ramos, T | 1 |
| Villarejo Galende, A | 1 |
| Porta Etessam, J | 1 |
| Thome-Souza, S | 1 |
| Moreira, B | 1 |
| Valente, KD | 1 |
| Borowicz, KK | 1 |
| Zadrozniak, M | 1 |
| Swiader, M | 1 |
| Kowalska, A | 1 |
| Kleinrok, Z | 1 |
| Czuczwar, SJ | 1 |
| Williams, JA | 1 |
| Barreiro, CJ | 1 |
| Nwakanma, LU | 1 |
| Lange, MS | 1 |
| Kratz, LE | 1 |
| Blue, ME | 1 |
| Berrong, J | 1 |
| Patel, ND | 1 |
| Gott, VL | 1 |
| Troncoso, JC | 1 |
| Johnston, MV | 1 |
| Baumgartner, WA | 1 |
| Chapman, A | 1 |
| Keane, PE | 1 |
| Meldrum, BS | 1 |
| Simiand, J | 1 |
| Vernieres, JC | 1 |
| Meldrum, B | 1 |
| Kouyoumdjian, JA | 1 |
| Marsden, CD | 1 |
| Sheehy, MP | 1 |
| van der Laan, JW | 1 |
| Bruinvels, J | 1 |
| Cools, AR | 1 |
| Chandra, V | 1 |
| Wharton, S | 1 |
| Spunt, AL | 1 |
| Simpson, DA | 1 |
| Wishnow, R | 1 |
| Gargulinski, RB | 1 |
| Pawlak, AM | 1 |
| Takajo, I | 1 |
| Ohi, T | 1 |
| Shiomi, K | 1 |
| Sugimoto, S | 1 |
| Matsukura, S | 1 |
| Tigges, P | 1 |
| Juckel, G | 1 |
| Schröter, A | 1 |
| Möller, HJ | 1 |
| Hegerl, U | 1 |
| Zhou, D | 1 |
| Wang, Y | 1 |
| Hopp, P | 1 |
| Kerling, F | 1 |
| Kirchner, A | 1 |
| Pauli, E | 1 |
| Stefan, H | 1 |
| Nutt, JG | 1 |
| Neophytides, AN | 1 |
| Lodish, JR | 1 |
| Costall, B | 1 |
| Naylor, RJ | 1 |
| Owen, RT | 1 |
| Paty, J | 1 |
| Bourgeois, M | 1 |
| Godwin-Austen, RB | 1 |
| Sethi, KD | 1 |
| Patel, BP | 1 |
| Löscher, W | 1 |
| Fisher, JE | 1 |
| Nau, H | 1 |
| Hönack, D | 1 |
| Kiuru, S | 1 |
| Iivanainen, M | 1 |
| Gastaut, JL | 1 |
| Mege, JL | 1 |
| Lang, AE | 1 |
5 reviews available for valproic acid and Movement Disorders
| Article | Year |
|---|---|
Valproate-associated Movement Disorder: A Literature Review.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticonvulsants; Child; Child, Preschool; Female; Humans | 2021 |
Movement disorders associated with antiseizure medications: A systematic review.
Topics: Anticonvulsants; Humans; Lacosamide; Movement Disorders; Phenobarbital; Valproic Acid | 2022 |
Mechanism of anticonvulsant action of valproate.
Topics: Animals; Aspartic Acid; Cats; Central Nervous System; Epilepsy; gamma-Aminobutyric Acid; Half-Life; | 1982 |
Pharmacology of GABA.
Topics: 4-Aminobutyrate Transaminase; Anxiety Disorders; Autonomic Nervous System; Barbiturates; Benzodiazep | 1982 |
Oculofacial-skeletal myorhythmia in central nervous system Whipple's disease: additional case and review of the literature.
Topics: Adult; Ceftriaxone; Follow-Up Studies; Humans; Male; Movement Disorders; Oculomotor Muscles; Sulfame | 1995 |
2 trials available for valproic acid and Movement Disorders
| Article | Year |
|---|---|
[Hemiballism treated with valproic acid: report of 2 cases].
Topics: Aged; Clinical Trials as Topic; Female; Humans; Hyperglycemia; Male; Middle Aged; Movement Disorders | 1984 |
GABA and movement disorders.
Topics: Anticonvulsants; Baclofen; Clinical Trials as Topic; Double-Blind Method; Dyskinesia, Drug-Induced; | 1981 |
27 other studies available for valproic acid and Movement Disorders
| Article | Year |
|---|---|
Motor Impairments Correlate with Social Deficits and Restricted Neuronal Loss in an Environmental Model of Autism.
Topics: Animals; Autism Spectrum Disorder; Brain; Disease Models, Animal; Female; Gait; Male; Mice, Inbred C | 2018 |
Posttrauma cotreatment with lithium and valproate: reduction of lesion volume, attenuation of blood-brain barrier disruption, and improvement in motor coordination in mice with traumatic brain injury.
Topics: Animals; Antimanic Agents; Blood-Brain Barrier; Brain Injuries; Disease Models, Animal; Drug Therapy | 2013 |
[Benign myoclonic epilepsy in infancy: natural history and behavioral and cognitive outcome].
Topics: Anticonvulsants; Attention Deficit Disorder with Hyperactivity; Child Behavior Disorders; Cognition | 2014 |
Sulindac attenuates valproic acid-induced oxidative stress levels in primary cultured cortical neurons and ameliorates repetitive/stereotypic-like movement disorders in Wistar rats prenatally exposed to valproic acid.
Topics: Animals; beta Catenin; Cells, Cultured; Disease Models, Animal; Female; Glycogen Synthase Kinase 3; | 2015 |
Pediatric Herpes Simplex Virus Encephalitis Complicated by N-Methyl-D-aspartate Receptor Antibody Encephalitis.
Topics: Acyclovir; Anti-N-Methyl-D-Aspartate Receptor Encephalitis; Antiviral Agents; Autoantibodies; Clonid | 2015 |
Considering Valproate as a Risk Factor for Rapid Exacerbation of Complex Movement Disorder in Progressed Stages of Late-Infantile CLN2 Disease.
Topics: Anticonvulsants; Child; Child, Preschool; Consciousness Disorders; Creatine Kinase; Deprescriptions; | 2016 |
Valproate induced cerebellar atrophy presenting as movement disorder.
Topics: Adult; Anticonvulsants; Atrophy; Cerebellum; Electroencephalography; Epilepsy, Tonic-Clonic; Female; | 2017 |
The differential diagnoses of parkinsonism: findings from a cohort of 1528 patients and a 10 years comparison in tertiary movement disorders clinics.
Topics: Aged; Antipsychotic Agents; Cinnarizine; Cohort Studies; Diagnosis, Differential; Female; Flunarizin | 2010 |
Difficult differential diagnosis of Unverricht-Lundborg disease with spontaneous kinesogenic myoclonus and movement disorder.
Topics: Diagnosis, Differential; Female; Humans; Movement Disorders; Myoclonus; Treatment Outcome; Unverrich | 2012 |
Phenytoin-induced acute orofacial dyskinesia.
Topics: Aged, 80 and over; Anticonvulsants; Epilepsy, Tonic-Clonic; Hematoma, Subdural; Humans; Male; Moveme | 2013 |
Late adverse effects of the coadministration of valproate and lamotrigine.
Topics: Adolescent; Anticonvulsants; Ataxia; Child; Drug Therapy, Combination; Epilepsy; Female; Headache; H | 2012 |
Interaction of the neurosteroid alphaxalone with conventional antiepileptic drugs in different types of experimental seizures.
Topics: Aminophylline; Amygdala; Anesthetics; Animals; Anticonvulsants; Avoidance Learning; Convulsants; Dru | 2002 |
Valproic acid prevents brain injury in a canine model of hypothermic circulatory arrest: a promising new approach to neuroprotection during cardiac surgery.
Topics: Animals; Apoptosis; Aspartic Acid; Behavior, Animal; Biomarkers; Brain; Brain Chemistry; Brain Damag | 2006 |
Dipropylacetate-induced quasi-morphine abstinence behaviour in the rat: participation of the locus coeruleus system.
Topics: Animals; Bis(4-Methyl-1-Homopiperazinylthiocarbonyl)disulfide; Disease Models, Animal; Humans; Locus | 1982 |
Amelioration of hemiballismus with sodium valproate.
Topics: Female; Humans; Middle Aged; Movement Disorders; Valproic Acid | 1982 |
[A case with symptomatic epilepsy and mirror movement due to unilateral schizencephaly].
Topics: Anticonvulsants; Brain; Epilepsy; Functional Laterality; Humans; Male; Middle Aged; Movement Disorde | 2000 |
Periodic motor impairments in a case of 48-hour bipolar ultrarapid cycling before and under treatment with valproate.
Topics: Aged; Antimanic Agents; Bipolar Disorder; Depressive Disorder; Handwriting; Humans; Male; Movement D | 2000 |
Influence on ictal seizure semiology of rapid withdrawal of carbamazepine and valproate in monotherapy.
Topics: Adult; Anticonvulsants; Automatism; Carbamazepine; Female; Humans; Male; Middle Aged; Movement Disor | 2002 |
Lowered erythrocyte-sedimentation rate with sodium valproate.
Topics: Adult; Afibrinogenemia; Blood Sedimentation; Fibrinogen; Humans; Movement Disorders; Valproic Acid | 1978 |
Gabaminergic and serotonergic modulation of the antidyskinetic effects of tiapride and oxiperomide in the model using 2-(N,N-dipropyl)animo-5,6-dihydroxytetralin.
Topics: 2-Naphthylamine; Aminobutyrates; Animals; Behavior, Animal; Benzamides; Benzimidazoles; Disease Mode | 1978 |
[Risk of psychotropic drug potentiation by dipropylacetamide (16 cases)].
Topics: Adult; Aged; Anticonvulsants; Antidepressive Agents; Cognition Disorders; Drug Synergism; Drug Thera | 1978 |
The treatment of the choreas and athetotic dystonias.
Topics: Adult; Athetosis; Benzodiazepines; Child; Chorea; Dystonia; Haloperidol; Humans; Levodopa; Movement | 1979 |
Inconsistent response to divalproex sodium in hemichorea/hemiballism.
Topics: Aged; Chorea; Dose-Response Relationship, Drug; Humans; Male; Movement Disorders; Thalamus; Valproic | 1990 |
Valproic acid in amygdala-kindled rats: alterations in anticonvulsant efficacy, adverse effects and drug and metabolite levels in various brain regions during chronic treatment.
Topics: Amygdala; Animals; Anticonvulsants; Body Temperature Regulation; Body Weight; Brain; Female; Kindlin | 1989 |
Camptocormia, a new side effect of sodium valproate.
Topics: Adult; Epilepsies, Myoclonic; Female; Humans; Movement Disorders; Posture; Valproic Acid | 1987 |
[Encephalopathy with asterixis induced by sodium valproate. Role of hyperammonemia without hepatic insufficiency].
Topics: Ammonia; Brain Diseases; Humans; Male; Middle Aged; Movement Disorders; Valproic Acid | 1985 |
Persistent hemiballismus with lesions outside the subthalamic nucleus.
Topics: Aged; Basal Ganglia Diseases; Corpus Striatum; Humans; Male; Middle Aged; Movement Disorders; Pimozi | 1985 |